Cardiology

Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.

Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

Califf discusses the difficulty patients face in accessing healthcare information despite rapid technology and treatment advancements.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

Lopez reviews findings from an analysis of ARISE-HF highlighting racial and ethnic differences in baseline characteristics and diabetic cardiomyopathy disease progression.

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.

Most modern GDMT components were prescribed to less than half of all patients included in the EMPACE study, indicating the need for strategies to enhance clinical adoption.

Michos discusses framing obesity as hyperandrogenism, with reductions in estrogen production contributing to higher visceral adiposity.

Study findings highlight the potential utility of cardiac catheterization as a targeted intervention in pre-kidney transplant cardiac risk stratification.

Pagidipati describes barriers to implementing guideline-directed medical therapy in patients with cardiometabolic diseases and steps needed to overcome them.

Khan’s presentation indicates that combination screening is the optimal method of identifying heart failure risk while minimizing the percentage of cases missed.

The ACHIEVE trial found use of spironolcatone was not associated with a statistically significant reduction in cardiovascular death or hospitalization for HF.

Semaglutide’s reduction in systolic blood pressure could indicate more potential for cardiovascular protection than simply its well-known glycemic benefits.

Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.

These data may upend the typically underperforming CETP inhibitor field with an accessible, oral medication for lowering LDL cholesterol.

Compared to age-matched controls, women with premature menopause had greater risks of all-cause mortality and multiple cardiovascular complications.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new treatment guidelines, in this week's essential news roundup.